Compare CAVA Group Inc (CAVA) vs TG Therapeutics Inc (TGTX) Price & Performance

CAVA Group (CAVA) is trading at $69.47, up 12.81% following strong Q2 2026 earnings that beat estimates with $0.19 EPS and 31.3% revenue growth. The stock shows bearish technical signals despite recent momentum, with key resistance at $62-64. Fundamentally, CAVA maintains robust revenue expansion and profitability with 24.69% gross margins, though valuation multiples remain elevated at P/E of 108.59.

The outlook remains positive given analyst consensus of 19 buys and $89.75 price target, representing 29% upside potential. Key risks include high valuation sensitivity, competitive pressures in fast-casual dining, and execution challenges in restaurant expansion. Recent same-store sales growth of 9% supports continued momentum if operational excellence persists.

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.